(HSY) Hershey - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US4278661081
Stock: Confectionery, Snacks, Baking, Beverages
Total Rating 59
Risk 75
Buy Signal 0.08
| Risk 5d forecast | |
|---|---|
| Volatility | 29.1% |
| Relative Tail Risk | -3.66% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.91 |
| Alpha | 26.23 |
| Character TTM | |
|---|---|
| Beta | 0.053 |
| Beta Downside | 0.000 |
| Drawdowns 3y | |
|---|---|
| Max DD | 45.25% |
| CAGR/Max DD | 0.02 |
EPS (Earnings per Share)
Revenue
Description: HSY Hershey March 04, 2026
The Hershey Company manufactures and sells confectionery and pantry items globally. The company operates through three segments: North America Confectionery, North America Salty Snacks, and International.
Product categories include chocolate and non-chocolate confectionery, gum and mints, protein bars, and pantry items like baking ingredients and toppings. Snack items comprise spreads, bars, popcorn, and pretzels. The company manages a portfolio of established brands, including Hersheys, Reeses, and Kit Kat.
Hershey distributes its products through various channels, including grocery stores, mass merchandisers, convenience stores, and wholesale clubs. This broad distribution network is typical for consumer staples companies. The company exports to approximately 65 countries, indicating a significant international presence within the packaged food sector.
To gain deeper insights into Hersheys financial health and market position, consider exploring its detailed reports on ValueRay.
Headlines to watch out for
- Cocoa and sugar price volatility impacts production costs
- North America confectionery sales drive revenue growth
- Salty snack expansion diversifies product portfolio
- International market penetration offers new growth avenues
- Consumer health trends influence product innovation and demand
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 883.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA 0.16 > 1.0 |
| NWC/Revenue: 4.93% < 20% (prev -1.52%; Δ 6.45% < -1%) |
| CFO/TA 0.17 > 3% & CFO 2.28b > Net Income 883.3m |
| Net Debt (4.48b) to EBITDA (1.76b): 2.55 < 3 |
| Current Ratio: 1.19 > 1.5 & < 3 |
| Outstanding Shares: last quarter (203.3m) vs 12m ago -0.11% < -2% |
| Gross Margin: 33.27% > 18% (prev 0.47%; Δ 3280 % > 0.5%) |
| Asset Turnover: 87.62% > 50% (prev 86.52%; Δ 1.10% > 0%) |
| Interest Coverage Ratio: 4.84 > 6 (EBITDA TTM 1.76b / Interest Expense TTM 207.4m) |
Altman Z'' 2.74
| A: 0.04 (Total Current Assets 3.59b - Total Current Liabilities 3.01b) / Total Assets 13.74b |
| B: 0.40 (Retained Earnings 5.50b / Total Assets 13.74b) |
| C: 0.08 (EBIT TTM 1.00b / Avg Total Assets 13.34b) |
| D: 0.63 (Book Value of Equity 5.72b / Total Liabilities 9.10b) |
| Altman-Z'' Score: 2.74 = A |
Beneish M -2.73
| DSRI: 0.87 (Receivables 729.5m/800.4m, Revenue 11.69b/11.20b) |
| GMI: 1.42 (GM 33.27% / 47.32%) |
| AQI: 1.16 (AQ_t 0.48 / AQ_t-1 0.42) |
| SGI: 1.04 (Revenue 11.69b / 11.20b) |
| TATA: -0.10 (NI 883.3m - CFO 2.28b) / TA 13.74b) |
| Beneish M-Score: -2.73 (Cap -4..+1) = A |
What is the price of HSY shares?
As of March 09, 2026, the stock is trading at USD 224.99 with a total of 1,038,072 shares traded.
Over the past week, the price has changed by -4.54%, over one month by -1.77%, over three months by +25.27% and over the past year by +24.44%.
Over the past week, the price has changed by -4.54%, over one month by -1.77%, over three months by +25.27% and over the past year by +24.44%.
Is HSY a buy, sell or hold?
Hershey has received a consensus analysts rating of 3.04.
Therefor, it is recommend to hold HSY.
- StrongBuy: 3
- Buy: 1
- Hold: 17
- Sell: 2
- StrongSell: 2
What are the forecasts/targets for the HSY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 229.7 | 2.1% |
| Analysts Target Price | 229.7 | 2.1% |
HSY Fundamental Data Overview March 05, 2026
P/E Trailing = 54.0785
P/E Forward = 28.7356
P/S = 4.0611
P/B = 10.303
P/EG = 44.9168
Revenue TTM = 11.69b USD
EBIT TTM = 1.00b USD
EBITDA TTM = 1.76b USD
Long Term Debt = 4.68b USD (from longTermDebt, last quarter)
Short Term Debt = 721.9m USD (from shortTermDebt, last quarter)
Debt = 5.40b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.48b USD (from netDebt column, last quarter)
Enterprise Value = 51.96b USD (47.48b + Debt 5.40b - CCE 925.9m)
Interest Coverage Ratio = 4.84 (Ebit TTM 1.00b / Interest Expense TTM 207.4m)
EV/FCF = 25.15x (Enterprise Value 51.96b / FCF TTM 2.07b)
FCF Yield = 3.98% (FCF TTM 2.07b / Enterprise Value 51.96b)
FCF Margin = 17.67% (FCF TTM 2.07b / Revenue TTM 11.69b)
Net Margin = 7.55% (Net Income TTM 883.3m / Revenue TTM 11.69b)
Gross Margin = 33.27% ((Revenue TTM 11.69b - Cost of Revenue TTM 7.80b) / Revenue TTM)
Gross Margin QoQ = 37.04% (prev 31.58%)
Tobins Q-Ratio = 3.78 (Enterprise Value 51.96b / Total Assets 13.74b)
Interest Expense / Debt = 0.89% (Interest Expense 48.1m / Debt 5.40b)
Taxrate = 13.40% (49.5m / 369.5m)
NOPAT = 869.5m (EBIT 1.00b * (1 - 13.40%))
Current Ratio = 1.19 (Total Current Assets 3.59b / Total Current Liabilities 3.01b)
Debt / Equity = 1.17 (Debt 5.40b / totalStockholderEquity, last quarter 4.64b)
Debt / EBITDA = 2.55 (Net Debt 4.48b / EBITDA 1.76b)
Debt / FCF = 2.17 (Net Debt 4.48b / FCF TTM 2.07b)
Total Stockholder Equity = 4.60b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.62% (Net Income 883.3m / Total Assets 13.74b)
RoE = 19.20% (Net Income TTM 883.3m / Total Stockholder Equity 4.60b)
RoCE = 10.82% (EBIT 1.00b / Capital Employed (Equity 4.60b + L.T.Debt 4.68b))
RoIC = 8.55% (NOPAT 869.5m / Invested Capital 10.17b)
WACC = 5.56% (E(47.48b)/V(52.89b) * Re(6.11%) + D(5.40b)/V(52.89b) * Rd(0.89%) * (1-Tc(0.13)))
Discount Rate = 6.11% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.51%
[DCF] Terminal Value 86.74% ; FCFF base≈2.01b ; Y1≈2.09b ; Y5≈2.41b
[DCF] Fair Price = 453.1 (EV 71.57b - Net Debt 4.48b = Equity 67.09b / Shares 148.1m; r=5.90% [WACC]; 5y FCF grow 4.52% → 2.90% )
EPS Correlation: -46.97 | EPS CAGR: -9.92% | SUE: 0.71 | # QB: 0
Revenue Correlation: 34.38 | Revenue CAGR: 4.02% | SUE: 0.94 | # QB: 1
EPS next Quarter (2026-06-30): EPS=1.62 | Chg7d=+0.000 | Chg30d=+0.380 | Revisions Net=+12 | Analysts=17
EPS current Year (2026-12-31): EPS=8.36 | Chg7d=-0.003 | Chg30d=+1.305 | Revisions Net=+21 | Growth EPS=+32.5% | Growth Revenue=+4.4%
EPS next Year (2027-12-31): EPS=9.79 | Chg7d=+0.066 | Chg30d=+1.396 | Revisions Net=+13 | Growth EPS=+17.1% | Growth Revenue=+2.5%
[Analyst] Revisions Ratio: +1.00 (12 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.1% (Discount Rate 7.9% - Earnings Yield 1.8%)
[Growth] Growth Spread = -1.7% (Analyst 4.4% - Implied 6.1%)
P/E Forward = 28.7356
P/S = 4.0611
P/B = 10.303
P/EG = 44.9168
Revenue TTM = 11.69b USD
EBIT TTM = 1.00b USD
EBITDA TTM = 1.76b USD
Long Term Debt = 4.68b USD (from longTermDebt, last quarter)
Short Term Debt = 721.9m USD (from shortTermDebt, last quarter)
Debt = 5.40b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.48b USD (from netDebt column, last quarter)
Enterprise Value = 51.96b USD (47.48b + Debt 5.40b - CCE 925.9m)
Interest Coverage Ratio = 4.84 (Ebit TTM 1.00b / Interest Expense TTM 207.4m)
EV/FCF = 25.15x (Enterprise Value 51.96b / FCF TTM 2.07b)
FCF Yield = 3.98% (FCF TTM 2.07b / Enterprise Value 51.96b)
FCF Margin = 17.67% (FCF TTM 2.07b / Revenue TTM 11.69b)
Net Margin = 7.55% (Net Income TTM 883.3m / Revenue TTM 11.69b)
Gross Margin = 33.27% ((Revenue TTM 11.69b - Cost of Revenue TTM 7.80b) / Revenue TTM)
Gross Margin QoQ = 37.04% (prev 31.58%)
Tobins Q-Ratio = 3.78 (Enterprise Value 51.96b / Total Assets 13.74b)
Interest Expense / Debt = 0.89% (Interest Expense 48.1m / Debt 5.40b)
Taxrate = 13.40% (49.5m / 369.5m)
NOPAT = 869.5m (EBIT 1.00b * (1 - 13.40%))
Current Ratio = 1.19 (Total Current Assets 3.59b / Total Current Liabilities 3.01b)
Debt / Equity = 1.17 (Debt 5.40b / totalStockholderEquity, last quarter 4.64b)
Debt / EBITDA = 2.55 (Net Debt 4.48b / EBITDA 1.76b)
Debt / FCF = 2.17 (Net Debt 4.48b / FCF TTM 2.07b)
Total Stockholder Equity = 4.60b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.62% (Net Income 883.3m / Total Assets 13.74b)
RoE = 19.20% (Net Income TTM 883.3m / Total Stockholder Equity 4.60b)
RoCE = 10.82% (EBIT 1.00b / Capital Employed (Equity 4.60b + L.T.Debt 4.68b))
RoIC = 8.55% (NOPAT 869.5m / Invested Capital 10.17b)
WACC = 5.56% (E(47.48b)/V(52.89b) * Re(6.11%) + D(5.40b)/V(52.89b) * Rd(0.89%) * (1-Tc(0.13)))
Discount Rate = 6.11% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.51%
[DCF] Terminal Value 86.74% ; FCFF base≈2.01b ; Y1≈2.09b ; Y5≈2.41b
[DCF] Fair Price = 453.1 (EV 71.57b - Net Debt 4.48b = Equity 67.09b / Shares 148.1m; r=5.90% [WACC]; 5y FCF grow 4.52% → 2.90% )
EPS Correlation: -46.97 | EPS CAGR: -9.92% | SUE: 0.71 | # QB: 0
Revenue Correlation: 34.38 | Revenue CAGR: 4.02% | SUE: 0.94 | # QB: 1
EPS next Quarter (2026-06-30): EPS=1.62 | Chg7d=+0.000 | Chg30d=+0.380 | Revisions Net=+12 | Analysts=17
EPS current Year (2026-12-31): EPS=8.36 | Chg7d=-0.003 | Chg30d=+1.305 | Revisions Net=+21 | Growth EPS=+32.5% | Growth Revenue=+4.4%
EPS next Year (2027-12-31): EPS=9.79 | Chg7d=+0.066 | Chg30d=+1.396 | Revisions Net=+13 | Growth EPS=+17.1% | Growth Revenue=+2.5%
[Analyst] Revisions Ratio: +1.00 (12 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.1% (Discount Rate 7.9% - Earnings Yield 1.8%)
[Growth] Growth Spread = -1.7% (Analyst 4.4% - Implied 6.1%)